{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "be:PDGFR",
      "entity_text" : "PDGFR",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5291",
      "entity_text" : "imatinib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "XREF_BIBR XREF_BIBR This allowed the possibility to exploit them in other indications (e.g., PDGFR inhibition by imatinib is used in BCR-ABL-negative chronic myeloid disorders), XREF_BIBR but this may also induce toxicities and side effects.",
  "reading_complete" : "2020-08-03T15:04:00Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T15:02:12Z",
  "trigger" : "inhibition",
  "evidence" : [ "PDGFR inhibition by imatinib" ],
  "pmc_id" : "6524858",
  "score" : 0
}